Genetic diseases affect 12 million people in America, and I happen have two of them. I was diagnosed with type 1 diabetes in 2011 and celiac in 2012. I have always had a strong passion of knowledge and I’ve always loved learning, and learning about my diseases is no exception. So in this report I will be telling you about Celiac, what it is, who it affects, how it affects, and what research is being done to cure it.
Celiac disease is an autoimmune disease where eating gluten, (the protein found it wheat, barley, rye, and some oats,) causes and immune reaction in the small intestine. Overtime, the reaction damages the lining of the small intestine and the villi. The villi are responsible for absorbing some nutrients, and when these villi are …show more content…
The HLA-DQ2 gene, is present in 95% of the people with celiac. Some events have also been correlated with the onset of the disease, such as pregnancy, surgery, and severe emotional stress. Some people are also more likely to get the disease, such as people with type one diabetes, down syndrome, autoimmune thyroid disease, and if someone else in your family has Celiac disease.
The first case of Celiac was seem back in a skeleton of a first century AD woman in Italy. She was around 20 years old with signs of malnutrition and failure to thrive. She also had the HLA-DQ2 gene. Ever since then the disease has shown its prevalence. Greek doctor Aretaeus of Cappadocia described some of his patients having “koiliakos” or suffering of the bowl. Today, around 3 million Americans are living with this disease, and sadly, around 97% of these people are undiagnosed. Also, 6% of people diagnosed with type one diabetes, will also have …show more content…
The only thing people can to do, is to go onto a strict gluten-free diet. But, some researches and scientists are in the process of testing a new drug, called AMG 174, for people with Celiac. AMG 174 is a human antibody that blocks IL-15. Now this IL-15 is thought to play a role in Celiac, being one of the of the main lymphocytes (a kind of white blood cells) that leads in the reaction caused by gluten. AMG 174 has been well received by healthy patients and people with rheumatoid arthritis in previous clinical trials. The research company Celimmune LLC, dosed its first patient in May, and the study is still going
Celiac disease is an autoimmune disease where eating gluten, (the protein found it wheat, barley, rye, and some oats,) causes and immune reaction in the small intestine. Overtime, the reaction damages the lining of the small intestine and the villi. The villi are responsible for absorbing some nutrients, and when these villi are …show more content…
The HLA-DQ2 gene, is present in 95% of the people with celiac. Some events have also been correlated with the onset of the disease, such as pregnancy, surgery, and severe emotional stress. Some people are also more likely to get the disease, such as people with type one diabetes, down syndrome, autoimmune thyroid disease, and if someone else in your family has Celiac disease.
The first case of Celiac was seem back in a skeleton of a first century AD woman in Italy. She was around 20 years old with signs of malnutrition and failure to thrive. She also had the HLA-DQ2 gene. Ever since then the disease has shown its prevalence. Greek doctor Aretaeus of Cappadocia described some of his patients having “koiliakos” or suffering of the bowl. Today, around 3 million Americans are living with this disease, and sadly, around 97% of these people are undiagnosed. Also, 6% of people diagnosed with type one diabetes, will also have …show more content…
The only thing people can to do, is to go onto a strict gluten-free diet. But, some researches and scientists are in the process of testing a new drug, called AMG 174, for people with Celiac. AMG 174 is a human antibody that blocks IL-15. Now this IL-15 is thought to play a role in Celiac, being one of the of the main lymphocytes (a kind of white blood cells) that leads in the reaction caused by gluten. AMG 174 has been well received by healthy patients and people with rheumatoid arthritis in previous clinical trials. The research company Celimmune LLC, dosed its first patient in May, and the study is still going